519 related articles for article (PubMed ID: 35175500)
1. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK; Powles T; Burotto M; Escudier B; Bourlon MT; Zurawski B; Oyervides Juárez VM; Hsieh JJ; Basso U; Shah AY; Suárez C; Hamzaj A; Goh JC; Barrios C; Richardet M; Porta C; Kowalyszyn R; Feregrino JP; Żołnierek J; Pook D; Kessler ER; Tomita Y; Mizuno R; Bedke J; Zhang J; Maurer MA; Simsek B; Ejzykowicz F; Schwab GM; Apolo AB; Motzer RJ;
N Engl J Med; 2021 Mar; 384(9):829-841. PubMed ID: 33657295
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
[TBL] [Abstract][Full Text] [Related]
5. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
Liu R; Qiu K; Wu J; Jiang Y; Wu P; Pang J
Immunotherapy; 2022 Aug; 14(11):859-869. PubMed ID: 35754404
[TBL] [Abstract][Full Text] [Related]
7. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
8. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.
McGregor B; Mortazavi A; Cordes L; Salabao C; Vandlik S; Apolo AB
Cancer Treat Rev; 2022 Feb; 103():102333. PubMed ID: 35033866
[TBL] [Abstract][Full Text] [Related]
9. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
Liao W; Lei W; Feng M; Yang Y; Wu Q; Zhou K; Bai L; Wen F; Li Q
Adv Ther; 2021 Dec; 38(12):5662-5670. PubMed ID: 34664194
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Powles T; Burotto M; Escudier B; Apolo AB; Bourlon MT; Shah AY; Suárez C; Porta C; Barrios CH; Richardet M; Gurney H; Kessler ER; Tomita Y; Bedke J; George S; Scheffold C; Wang P; Fedorov V; Motzer RJ; Choueiri TK
ESMO Open; 2024 May; 9(5):102994. PubMed ID: 38642472
[TBL] [Abstract][Full Text] [Related]
12. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Huo S; Del Tejo V; Du EX; Yang X; Betts KA; Choueiri TK; McGregor B
Clin Drug Investig; 2022 Jul; 42(7):611-622. PubMed ID: 35696045
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
Tran BD; Li J; Ly N; Faggioni R; Roskos L
Cancer Chemother Pharmacol; 2023 Feb; 91(2):179-189. PubMed ID: 36625894
[TBL] [Abstract][Full Text] [Related]
14. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
Front Public Health; 2022; 10():954264. PubMed ID: 36159269
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus cabozantinib for advanced renal cell carcinoma.
Benjamin DJ; Nolla K; Cella D
Future Oncol; 2022 Dec; 18(39):4351-4359. PubMed ID: 36655774
[TBL] [Abstract][Full Text] [Related]
17. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
